@FiercePharma: Will Bausch + Lomb choose IPO over a sale to pharma? Related Q: Can Warburg Pincus get its $10B+ asking price? More | Follow @FiercePharma
@EricPFierce: COO Perez says Cubist well positioned in new hospital-centric payer world. "The world has turned and we are Cinderella now." | Follow @EricPFierce
@AlisonBFierce: Altravax landed $1.2M from NIAID to advance its dengue vaccine and hepatitis therapeutic. More | Follow @AlisonBFierce
> After evaluating options for its diabetes unit, Bayer no longer plans to sell the business, Bayer Healthcare CEO Joerg Reinhardt said. Report
> Teva Pharmaceutical Industries ($TEVA) hiked the prices of its two lead drugs, the MS treatment Copaxone and Parkinson's disease drug Azilect, by 10% to help make up for anticipated losses to competition from oral treatments. Report
> A U.S. appeals court put the pharma industry on the hook for rebates and price caps issued by the Department of Defense to curb spending on drugs. Report
> India's Biocon won approval in its home country for Itolizumab, a biologic treatment for psoriasis; a launch there will pave the way for submission to FDA, the company said. Report
> China's drug agency is calling on the World Health Organization to buy more drugs made in China. Report
> GlaxoSmithKline ($GSK) won regulatory approval in India to purchase an additional 31.8% stake in its Indian subsidiary to boost its ownership to 75%. Report
@FierceMedDev: Samsung med device sales spike in 2012. Item | Follow @FierceMedDev
@MarkHFierce: Abbott is beginning a bioresorbable stent trial in the U.S. Big news for the company and its stent rivals alike. More | Follow @MarkHFierce
@DamianFierce: $LIFE is teaming up with Boston Children's Hospital to develop genomics-based diagnostics. News | Follow @DamianFierce
> LabCorp inks companion diagnostic deal with Verastem. News
> JPM: U.S., EU regulators to consider GE's Alzheimer's imaging agent. Story
Biotech News
@FierceBiotech: Buyout buzz: Biopharma players staying focused on bolt-on deals. Report | Follow @FierceBiotech
@JohnCFierce: Medicines Co. spikes after anti-clotting drug impresses in second run at PhIII. Story | Follow @JohnCFierce
> Baxter preps BLA on successful end to PhIII hemophilia drug study. More
> Payer risk outrivals regulatory jitters as biggest biotech hurdle. News
Drug Delivery News
> Alnylam prepares for U.K. Phase I and plans for the future. Article
> Agile snags $15M loan to push pipeline products forward. News
> FDA approves EMD Serono-Pfizer's Rebif auto-injector. Item
> FDA grants orphan label to eye cancer chemo-delivery combo. Story
Biomarkers News
> Biomarkers could tag chemo heart risk. Item
> Stem cell factor could improve ovarian cancer prognosis. Article
> Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test. News
> New target could improve treatment of deadly pancreatic cancer. Story
And Finally... DNA pioneer James Watson figures antioxidant vitamins and therapies could hinder cancer treatment. Report